Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 5,000,000 target

The Pediatric Anesthesia Quality Improvement Project

The Society for Pediatric Anesthesia

NCT00674388

Recruiting 150,000 target

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

Children's Hospital of Philadelphia

NCT02493478

Recruiting 100,000 target

Product Surveillance Registry

Medtronic

NCT01524276

Recruiting 100,000 target

Caris Biorepository Research Protocol

Caris Science

NCT01499394

Recruiting 99,999 target

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Center for International Blood and Marrow Transplant Research

NCT01351545

Recruiting 75,000 target

Project: Every Child for Younger Patients With Cancer

Children's Oncology Group

NCT02402244

Recruiting 50,000 target

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio

NCT03452774

Recruiting 40,000 target

Registry Study for Radiation Therapy Outcomes

Proton Collaborative Group

NCT01255748

Recruiting NA 36,503 target

Supraglottic Airway for Resuscitation Trial

Children's Hospital of Philadelphia

NCT07150923

Recruiting Phase 3 32,000 target

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

Pfizer

NCT07282665

Recruiting Phase 3 25,500 target

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

BioNTech SE

NCT07300839

Recruiting 25,000 target

Parkinson's Foundation PD GENEration Genetic Registry

Parkinson's Foundation

NCT04994015

Recruiting Phase 4 20,000 target

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Duke University

NCT04262206

Recruiting 20,000 target

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Medtronic

NCT00271180

Recruiting 15,000 target

Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

Heart Rhythm Clinical and Research Solutions

NCT04088071

Recruiting Phase 3 15,000 target

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Janssen Research & Development

NCT05702034

Recruiting 14,000 target

Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes

Baylor Research Institute

NCT01904851

Recruiting NA 13,000 target

Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial

Washington University School of Medicine

NCT05991453

Recruiting 12,000 target

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Genzyme, a Sanofi Company

NCT00358943

Recruiting Phase 3 11,000 target

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Alnylam Pharmaceuticals

NCT07181109

Recruiting Phase 3 11,000 target

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Amgen

NCT07136012

Recruiting 10,000 target

Tracking Results of Ablations to Combat AF Registry Generation 2

AtriCure

NCT05111015

Recruiting Phase 3 10,000 target

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Novo Nordisk A/S

NCT06118281

Recruiting NA 9,500 target

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

NRG Oncology

NCT05080673

Recruiting 9,000 target

Fabry Disease Registry & Pregnancy Sub-registry

Genzyme, a Sanofi Company

NCT00196742

Recruiting Phase 4 7,410 target

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

VA Office of Research and Development

NCT02915198

Recruiting Phase 4 6,000 target

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Duke University

NCT06909565

Recruiting Phase 3 5,951 target

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

NCT03959085

Recruiting Phase 3 5,600 target

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Novo Nordisk A/S

NCT05636176

Recruiting Phase 3 5,500 target

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

AstraZeneca

NCT05952557

Recruiting Phase 3 5,056 target

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Amgen

NCT07037459

Recruiting 5,000 target

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

National Cancer Institute LAO

NCT02474160

Recruiting 5,000 target

Functional Assessment in Liver Transplantation

University of California, San Francisco

NCT03228290

Recruiting 5,000 target

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Children's Oncology Group

NCT00736749

Recruiting 5,000 target

The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry

Yale University

NCT06030063

Recruiting 5,000 target

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Boston Scientific Corporation

NCT04674969

Recruiting 5,000 target

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Duke University

NCT04278404

Recruiting 5,000 target

CureDuchenne Link®: A Resource for Research

CureDuchenne

NCT04972604

Recruiting Phase 3 4,800 target

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

AstraZeneca

NCT06307652

Recruiting Phase 3 4,500 target

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Eli Lilly and Company

NCT07165028

Recruiting Phase 3 4,300 target

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

AstraZeneca

NCT05774951

Recruiting Phase 2 4,292 target

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

BioNTech SE

NCT05543616

Recruiting Phase 3 4,220 target

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Stemline Therapeutics

NCT06492616

Recruiting NA 4,000 target

The Fourth Left Atrial Appendage Occlusion Study

Hamilton Health Sciences Corporation

NCT05963698

Recruiting Phase 3 3,960 target

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NRG Oncology

NCT05879926

Recruiting 3,784 target

Abbott Vascular Medical Device Registry

Abbott Medical Devices

NCT04573660

Recruiting Phase 3 3,680 target

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

NCT06058377

Recruiting Phase 3 3,200 target

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Icahn School of Medicine at Mount Sinai

NCT04045665

Recruiting Phase 3 3,040 target

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Bristol-Myers Squibb

NCT07116967

Recruiting 3,000 target

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

American Thrombosis and Hemostasis Network

NCT04398628

Recruiting NA 3,000 target

Optimizing Tracheal Intubation Outcomes and Neonatal Safety

Children's Hospital of Philadelphia

NCT05838690

Recruiting NA 3,000 target

Smart Checklist Implementation for Pediatric Tracheal Intubations in the ICU- Multicenter Study

Children's Hospital of Philadelphia

NCT06085326

Recruiting 3,000 target

EXtubation Related Complications - the EXTUBE Study (EXTUBE)

University Health Network, Toronto

NCT06442930

Recruiting NA 2,998 target

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Melanoma and Skin Cancer Trials Limited

NCT03860883

Recruiting Phase 2 2,900 target

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

NCT05564377

Recruiting NA 2,400 target

MiSight 1 Day Safety Post-Approval Study

CooperVision

NCT05285527

Recruiting Phase 3 2,400 target

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

SWOG Cancer Research Network

NCT05929768

Recruiting Phase 3 2,330 target

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Pfizer

NCT06679140

Recruiting Phase 3 2,320 target

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Sanofi

NCT06824194

Recruiting Phase 3 2,140 target

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Canadian Cancer Trials Group

NCT03488693

Recruiting NA 2,136 target

Left vs Left Randomized Clinical Trial

Baylor College of Medicine

NCT05650658

Recruiting Phase 3 2,050 target

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

NCT05050084

Recruiting 2,020 target

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Guardant Health

NCT05059444

Recruiting 2,000 target

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

W.L.Gore & Associates

NCT06218875

Recruiting Phase 2 2,000 target

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

NCT05564390

Recruiting 2,000 target

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

Arkansas Children's Hospital Research Institute

NCT05550298

Recruiting 2,000 target

Pompe Disease Registry Protocol

Genzyme, a Sanofi Company

NCT00231400

Recruiting Phase 3 2,000 target

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

DalCor Pharmaceuticals

NCT05918861

Recruiting 2,000 target

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Wake Forest University Health Sciences

NCT06418204

Recruiting 2,000 target

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

ECOG-ACRIN Cancer Research Group

NCT06002828

Recruiting 2,000 target

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Elephas

NCT07327489

Recruiting 2,000 target

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Alliance for Clinical Trials in Oncology

NCT05334069

Recruiting NA 1,956 target

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

NRG Oncology

NCT04251052

Recruiting Phase 2 1,912 target

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

NRG Oncology

NCT05174169

Recruiting Phase 3 1,875 target

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

NCT05675410

Recruiting Phase 3 1,800 target

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

AstraZeneca

NCT06120491

Recruiting Phase 3 1,780 target

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Children's Oncology Group

NCT03067181

Recruiting Phase 3 1,700 target

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera

NCT07284901

Recruiting Phase 3 1,670 target

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NRG Oncology

NCT04852887

Recruiting Phase 3 1,656 target

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Children's Oncology Group

NCT06401330

Recruiting Phase 3 1,650 target

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Akero Therapeutics

NCT06215716

Recruiting NA 1,600 target

The CONFORM Pivotal Trial

Conformal Medical

NCT05147792

Recruiting 1,600 target

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

NCT04314401

Recruiting Phase 3 1,600 target

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Summit Therapeutics

NCT05899608

Recruiting 1,600 target

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Bristol-Myers Squibb

NCT05489705

Recruiting Phase 3 1,524 target

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Alliance for Clinical Trials in Oncology

NCT06876714

Recruiting NA 1,500 target

Telehealth Multi-Component Optional Model (MOM) Study

University of Arkansas

NCT06095960

Recruiting Phase 2 1,500 target

HEALEY ALS Platform Trial - Master Protocol

Merit E. Cudkowicz, MD

NCT04297683

Recruiting 1,500 target

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Bristol-Myers Squibb

NCT07379827

Recruiting 1,500 target

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Jaeb Center for Health Research

NCT05589714

Recruiting Phase 3 1,500 target

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

AbbVie

NCT06012240

Recruiting Phase 3 1,450 target

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

ECOG-ACRIN Cancer Research Group

NCT04566328

Recruiting NA 1,440 target

Delivering HOPE (Helping Women Optimize Prenatal Equity)

University of Arkansas

NCT06814509

Recruiting Phase 3 1,410 target

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Pfizer

NCT07222566

Recruiting Phase 2 1,400 target

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

North American Consortium for Histiocytosis

NCT02205762

Recruiting Phase 3 1,400 target

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Novartis Pharmaceuticals

NCT05827081

Recruiting 1,350 target

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

Children's Hospital Medical Center, Cincinnati

NCT02523118

Recruiting Phase 3 1,350 target

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

89bio

NCT06318169

Recruiting Phase 3 1,328 target

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

AbbVie

NCT05889182

Recruiting Phase 3 1,300 target

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

NRG Oncology

NCT05705401

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →